DIFF Biotech

Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the development of next-generation vaccines and viral vector therapies. The company utilizes its proprietary Viraltech Architect Platform to engineer innovative treatments, including its lead candidate DIFF-flu, a replication-restricted nasal spray influenza vaccine that recently received clinical trial approval from the NMPA. DIFF Biotech's research spans mucosal immune vaccines, oncolytic viruses, and gene therapies, supported by a modular "Design-Construct-Verify-Learn" (DCVL) approach to viral vector editing. Recognized as a "Quasi-Unicorn" and a high-tech enterprise, the company maintains a robust intellectual property portfolio with over 70 patent applications globally. In addition to its internal pipeline, DIFF Biotech provides specialized CRO and manufacturing services to the broader life sciences industry.